Avak Kahvejian, Ph.D. is a life sciences inventor, entrepreneur, and CEO who has co-founded more than ten companies. Since 2011, he has been a partner at Flagship Pioneering, where he leads a team to invent and launch new therapeutic platforms. His work has led to the creation of multiple high-value public and private companies including Seres Therapeutics (NASDAQ: MCRB); the first microbiome therapy platform; Ring Therapeutics; Cellarity; Laronde; Generate Biomedicines; ProFound Therapeutics; Ampersand Biomedicines; Cygnal Therapeutics; Rubius Therapeutics; and Codiak BioSciences .
Avak served as founding President and CEO of Rubius from 2013-2017, founding CEO of Ring Therapeutics, Cellarity, and Laronde from 2017 to 2020, as co-CEO of Generate from 2017 to 2021. He is on the boards of Cellarity and Laronde and Chairman of Ring. He is currently the Founding CEO and a board member of ProFound Therapeutics and Ampersand Biomedicines.
Avak serves as the Chairman of the Board of the International Institute of New England, an institution which creates opportunities for refugees and immigrants to succeed through resettlement, education, career advancement and pathways to citizenship. He is also on the Advisory Board of the Foundation for Armenian Science and Technology (FAST).
Avak earned his Ph.D. and B.Sc. in Biochemistry from McGill University in Montreal, Canada.